Overview

Full Product Details

Author:   Abhijit Ray ,  Punit Kumar Srivastava
Publisher:   Taylor & Francis Inc
Imprint:   CRC Press Inc
Weight:   0.635kg
ISBN:  

9781439851401

ISBN 10:   1439851409
Pages:   382
Publication Date:   28 November 2011
Audience:   College/higher education ,  General/trade ,  Tertiary & Higher Education ,  General
Format:   Hardback
Publisher's Status:   Active
Availability:   In Print  
This item will be ordered in for you from one of our suppliers. Upon receipt, we will promptly dispatch it out to you. For in store availability, please contact us.

Table of Contents

Obstructive Airway Diseases: Epidemiology, Etiology, and Therapeutic Options. Lipids: Reservoir of Drug Targets. Phospholipase A2 as a Potential Drug Target for Airway Disorders. 5-Lipoxygenase Pathway: A Validated Route to Drug Discovery. Leukotriene Receptor Antagonists and FLAP Inhibitors. EETs and Oxo-ETE in Airway Diseases. The Eosinophil Chemoattractant 5-Oxo-ET. Cyclooxygenases and Prostaglandin Receptors. Proresolution Mediators of Inflammation in Airway Diseases: Resolvins Pave New Directions. Platelet-Activating Factor Antagonist Therapy for Airway Disorders. Lysophosphatidic Acid in Airway Inflammation. Sphingolipids in Airway Inflammation. Protein Kinase C Isozymes and Airway Inflammation. Prospects for PI3 Kinase Signaling Inhibition in Obstructive Airway Diseases. Index.

Reviews

Author Information

Abhijit Ray has worked in human trials with molecules designed to treat airway inflammation associated with asthma and COPD and has published more than 60 articles in peer-reviewed journals. He has been the senior director and head of biology research at Daiichi Sankyo Life Science Research Centre India, Gurgaon since July 2010. As a member of the drug discovery team, he manages a group of 60 scientists engaged in discovery research for drugs in the areas of infectious and inflammatory diseases. Punit Srivastava has been a group leader of biology at Daiichi Sankyo Life Science Research Centre India, Gurgaon since July 2010. He was a member of the drug discovery group of Ranbaxy Laboratories Ltd. from 2004 to June 2010 and has worked for more than six years in drug discovery research, which has resulted in one molecule entering human trial for COPD. He has published more than 15 articles in peer-reviewed journals and filed at least six patents. As a member of the drug discovery team at Daiichi Sankyo, he is leading projects in the area of inflammation.

Tab Content 6

Author Website:  

Customer Reviews

Recent Reviews

No review item found!

Add your own review!

Countries Available

All regions